MindWalk HoldingsHYFT -0.31%38 Days Payable is 180.83 as of Jan. 2026, which is 38% above its 10-year median of 131.20. GuruFocus rates HYFT with a GF Score™ of 38/100 and a GF Value™ of $0.60 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 703 Biotechnology companies, MindWalk Holdings ranks better than 51.64% on this metric.
The historical rank and industry rank for MindWalk Holdings's Days Payable or its related term are showing as below:
HYFT'
s Days Payable Range Over the Past 10 Years
Min: 53.53 Med: 131.2 Max: 248.41
Current: 119.09
During the past 13 years, MindWalk Holdings's highest Days Payable was 248.41. The lowest was 53.53. And the median was 131.20.
HYFT's Days Payable is ranked better than 51.64% of 703
companies
in the Biotechnology industry
Industry Median: 113.76
vs HYFT: 119.09
MindWalk Holdings's Days Payable
declined
from Jan. 2025 (472.88) to Jan. 2026 (180.83).
It may suggest that MindWalk Holdingsaccelerated paying its suppliers.
MindWalk Holdings Days Payable Related Terms
MindWalk Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for MindWalk Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, MindWalk Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindWalk Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindWalk Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where MindWalk Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
MindWalk Holdings's Days Payable for the fiscal year that ended in Apr. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindWalk Holdings (HYFT) has a Days Payable of 180.83 as of Jan. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MindWalk Holdings and its competitors. This is 38% above median its historical median of 131.20. Over the past decade, MindWalk Holdings' Days Payable has ranged from 53.53 to 248.41. According to the industry distribution chart, MindWalk Holdings ranks #340 out of 703 companies in the Biotechnology industry, placing it in the top 48.4%.
Is MindWalk Holdings' Days Payable too high?
MindWalk Holdings' current Days Payable of 180.83 is 38% above median its 10-year median of 131.20. Over the past 10 years, this metric has ranged from a low of 53.53 to a high of 248.41. The Biotechnology industry median Days Payable is 113.76. MindWalk Holdings' value of 180.83 is 59% above this industry median. Based on the distribution chart, MindWalk Holdings ranks #340 out of 703 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MindWalk Holdings has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MindWalk Holdings' Days Payable compare to ANVS and GANX?
According to the Biotechnology industry distribution chart, MindWalk Holdings ranks #340 out of 703 companies for Days Payable. This puts MindWalk Holdings in the upper half of its industry. The industry median Days Payable is 113.76. MindWalk Holdings' value of 180.83 is 59% above this benchmark. Historically, MindWalk Holdings' own Days Payable has ranged from 53.53 to 248.41 over the past decade. While the company's 10-year median is 131.20 vs. the industry median of 113.76, MindWalk Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MindWalk Holdings's current Days Payable of 180.83 is 59% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on MindWalk Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindWalk Holdings's current Days Payable is 180.83, which is 38% above median its own 10-year median of 131.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindWalk Holdings stock overvalued right now?
Based on GuruFocus' analysis, MindWalk Holdings (HYFT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.60, compared to a current price of $1.62 — trading 169.2% above its estimated fair value. The current Days Payable is 180.83, which is 38% above median its 10-year median of 131.20 and 59% above the Biotechnology industry median of 113.76. MindWalk Holdings' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For MindWalk Holdings (HYFT), the current Days Payable is 180.83 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MindWalk Holdings (HYFT) Overvalued in 2026?
Based on GuruFocus' analysis, MindWalk Holdings stock appears to be overvalued.
The current stock price of $1.62 is trading 169.2% above its estimated GF Value™ of $0.60.
GuruFocus considers MindWalk Holdings to be Significantly Overvalued.
Key valuation signals for HYFT:
Days Payable: 180.83 (38% above median its 10-year median of 131.20)
GF Value™: $0.60 vs. price of $1.62 (169.2% above fair value)
Industry Position: 59% above the Biotechnology median (#340 of 703)
No single metric tells the full story. See the HYFT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MindWalk Holdings Corp is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
38GF Score
Get the complete analysis for HYFT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HYFT has been successfully added to your 
